title: The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.
abstract: The acquired ability of tamoxifen to stimulate tumor growth has been suggested as one mechanism for the development of treatment failure in breast cancer. We have reported that tamoxifen-stimulated MCF-7 breast tumors in nude mice display reduced tamoxifen levels as compared with tamoxifen-inhibited tumors and an altered metabolite profile with isomerization of trans-4-hydroxytamoxifen to a weak antiestrogen and the production of metabolite E, an estrogenic metabolite. To investigate further the importance of tamoxifen metabolism in this model, we quantified levels of tamoxifen and major metabolites in tamoxifen-stimulated as compared with tamoxifen-inhibited MCF-7 tumors growing in nude mice and employed tamoxifen analogs resistant to metabolism. Tamoxifen-stimulated tumors have a relative abundance of cis-4-hydroxytamoxifen and metabolite E. However, in vivo treatment of mice carrying tamoxifen-stimulated tumors with fixed-ring nonisomerizable tamoxifen analogs or with nafoxidine, a nonsteroidal antiestrogen with a different structure, nonetheless resulted in tumor growth stimulation. Tumors were also stimulated by a deoxytamoxifen analog resistant to conversion to metabolite E. Growth of tamoxifen-stimulated tumors was inhibited by a pure steroidal antiestrogen, ICI 182,780, suggesting the need for clinical trials of this drug in patients with tamoxifen resistance. Growth of tamoxifen-stimulated tumors was further stimulated by estrogen replenishment, and this estrogen stimulation could be blocked by tamoxifen indicating that tamoxifen has both agonist and antagonist properties in these tumors. This study suggests that tamoxifen-stimulated tumor growth in this model is not due to isomerization or metabolism of tamoxifen to less antiestrogenic or more estrogenic metabolites. The mechanisms by which tamoxifen acquires more potent in vivo agonist properties, resulting in tumor growth stimulation over time, remain to be defined.
authors.affiliation: Department of Medicine, University of Texas Health Science Center at San Antonio 78284.
authors.forename: C K
authors.initials: CK
authors.lastname: Osborne
authors.forename: M
authors.initials: M
authors.lastname: Jarman
authors.forename: R
authors.initials: R
authors.lastname: McCague
authors.forename: E B
authors.initials: EB
authors.lastname: Coronado
authors.forename: S G
authors.initials: SG
authors.lastname: Hilsenbeck
authors.forename: A E
authors.initials: AE
authors.lastname: Wakeling
mesh_terms: D000818:Animals; D002851:Chromatography, High Pressure Liquid; D003864:Depression, Chemical; D004195:Disease Models, Animal; D004354:Drug Screening Assays, Antitumor; D005260:Female; D007536:Isomerism; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy* / Q000378:metabolism*; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D013268:Stimulation, Chemical; D013629:Tamoxifen / Q000031:analogs & derivatives / Q000032:analysis / Q000493:pharmacokinetics* / Q000494:pharmacology* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured / Q000187:drug effects
chemical_list: D013629:Tamoxifen